{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:03:33Z","timestamp":1789178613284,"version":"build-2803163510"},"reference-count":28,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ipsen"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>There are limited real-world data on the use of botulinum toxin type A (BoNT-A) in patients with multiple sclerosis (MS). Accordingly, this nationwide, population-based, retrospective cohort study aimed to describe BoNT-A treatment trends in patients with MS between 2014 and 2020 in France. This study extracted data from the French National Hospital Discharge Database (Programme de M\u00e9dicalisation des Syst\u00e8mes d\u2019Information, PMSI) covering the entire French population. Among 105,206 patients coded with MS, we identified those who received \u22651 BoNT-A injection, administered within striated muscle for MS-related spasticity and\/or within the detrusor smooth muscle for neurogenic detrusor overactivity (NDO). A total of 8427 patients (8.0%) received BoNT-A injections for spasticity, 52.9% of whom received \u22653 BoNT-A injections with 61.9% of the repeated injections administered every 3 to 6 months. A total of 2912 patients (2.8%) received BoNT-A injections for NDO, with a mean of 4.7 injections per patient. Most repeated BoNT-A injections within the detrusor smooth muscle (60.0%) were administered every 5 to 8 months. There were 585 patients (0.6%) who received both BoNT-A injections within striated muscle and the detrusor smooth muscle. Overall, our study highlights a broad range of BoNT-A treatment practices between 2014 and 2020 in patients with MS.<\/jats:p>","DOI":"10.3390\/toxins15040280","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T01:35:00Z","timestamp":1681349700000},"page":"280","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Djamel","family":"Bensmail","sequence":"first","affiliation":[{"name":"Department of Physical and Rehabilitation Medicine, Raymond-Poincar\u00e9 Teaching Hospital, APHP, Universit\u00e9 Paris-Saclay, 92380 Garches, France"},{"name":"Unit\u00e9 INSERM 1179, University of Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-Le-Bretonneux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0631-8541","authenticated-orcid":false,"given":"Pierre","family":"Karam","sequence":"additional","affiliation":[{"name":"PKCS, 69130 Ecully, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Forestier","sequence":"additional","affiliation":[{"name":"Ipsen, 92100 Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Loze","sequence":"additional","affiliation":[{"name":"Ipsen, 92100 Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-0724","authenticated-orcid":false,"given":"Jonathan","family":"L\u00e9vy","sequence":"additional","affiliation":[{"name":"Department of Physical and Rehabilitation Medicine, Raymond-Poincar\u00e9 Teaching Hospital, APHP, Universit\u00e9 Paris-Saclay, 92380 Garches, France"},{"name":"Unit\u00e9 INSERM 1179, University of Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-Le-Bretonneux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"ref_1","unstructured":"Hui, D., and Arg\u00e1ez, C. (2023, January 20). Onabotulinum Toxin A (Botox) for Spasticity Associated with Multiple Sclerosis, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK571918\/."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Anandan, C., and Jankovic, J. (2021). Botulinum toxin in movement disorders: An update. Toxins, 13.","DOI":"10.3390\/toxins13010042"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1007\/s10072-022-06424-x","article-title":"Diagnostic and therapeutic recommendations in adult dystonia: A joint document by the Italian Society of Neurology, the Italian Academy for the Study of Parkinson\u2019s Disease and Movement Disorders, and the Italian Network on Botulinum Toxin","volume":"43","author":"Romano","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Choudhury, S., Baker, M.R., Chatterjee, S., and Kumar, H. (2021). Botulinum toxin: An update on pharmacology and newer products in development. Toxins, 13.","DOI":"10.3390\/toxins13010058"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5489\/cuaj.4058","article-title":"Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines","volume":"11","author":"Aharony","year":"2017","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11940-017-0470-5","article-title":"Botulinum toxin treatment in multiple sclerosis\u2014A review","volume":"19","author":"Safarpour","year":"2017","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.rehab.2017.10.001","article-title":"Non-pharmacological interventions for spasticity in adults: An overview of systematic reviews","volume":"62","author":"Khan","year":"2019","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00415-016-8304-z","article-title":"Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: Review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force","volume":"264","author":"Dressler","year":"2017","journal-title":"J. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/ene.14110","article-title":"Italian consensus on treatment of spasticity in multiple sclerosis","volume":"27","author":"Comi","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_10","unstructured":"French National Authority for Health (Haute Autorit\u00e9 de Sant\u00e9) (2023, January 20). R\u00e9\u00e9ducation \u00e0 la Phase Chronique de l\u2019AVC de l\u2019Adulte: Pertinence, Indications et Modalit\u00e9s [Rehabilitation in the Chronic Stage after Stroke in Adults: Relevance, Indications, and Modalities]. Available online: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2022-07\/_reco_321_argumentaire_avc_mel_lg_v0_mg.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1590\/s1677-5538.ibju.2021.0098","article-title":"Neurogenic bladder\u2014Concepts and treatment recommendations","volume":"48","author":"Truzzi","year":"2022","journal-title":"Int. Braz. J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hsieh, P.F., Chiu, H.C., Chen, K.C., Chang, C.H., and Chou, E.C. (2016). Botulinum toxin A for the treatment of overactive bladder. Toxins, 8.","DOI":"10.3390\/toxins8030059"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s10072-020-04392-8","article-title":"Botulinum toxin for the management of spasticity in multiple sclerosis: The Italian botulinum toxin network study","volume":"41","author":"Moccia","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_14","first-page":"2055217317730421","article-title":"Healthcare expenditure of multiple sclerosis patients in 2013: A nationwide study based on French health administrative databases","volume":"3","author":"Lefeuvre","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Novarella, F., Carotenuto, A., Cipullo, P., Iodice, R., Cassano, E., Spiezia, A.L., Capasso, N., Petracca, M., Falco, F., and Iacovazzo, C. (2022). Persistence with botulinum toxin treatment for spasticity symptoms in multiple sclerosis. Toxins, 14.","DOI":"10.3390\/toxins14110774"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1191\/1352458504ms1085oa","article-title":"Prevalence and treatment of spasticity reported by multiple sclerosis patients","volume":"10","author":"Rizzo","year":"2004","journal-title":"Mult. Scler."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/00207454.2012.762364","article-title":"Spasticity in multiple sclerosis: Results of a patient survey","volume":"123","author":"Vila","year":"2013","journal-title":"Int. J. Neurosci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.msard.2015.10.007","article-title":"Spasticity in multiple sclerosis: Associations with impairments and overall quality of life","volume":"5","author":"Milinis","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jfma.2013.10.009","article-title":"Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity","volume":"114","author":"Chen","year":"2015","journal-title":"J. Formos Med. Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101579","DOI":"10.1016\/j.rehab.2021.101579","article-title":"Time course response after single injection of botulinum toxin to treat spasticity after stroke: Systematic review with pharmacodynamic model-based meta-analysis","volume":"65","author":"Ojardias","year":"2022","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756287216672180","article-title":"Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder","volume":"9","author":"Sahai","year":"2017","journal-title":"Ther. Adv. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/nau.23352","article-title":"Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity","volume":"37","author":"Joussain","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/tcmj.tcmj_77_20","article-title":"Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?","volume":"33","author":"Chen","year":"2021","journal-title":"Tzu Chi Med. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3138\/ptc.2014-07","article-title":"Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments","volume":"67","author":"Cheung","year":"2015","journal-title":"Physiother. Can."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11910-019-0991-2","article-title":"Assessment and measurement of spasticity in MS: State of the evidence","volume":"19","author":"Hugos","year":"2019","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","article-title":"Satisfaction with botulinum toxin treatment: A cross-sectional survey of patients with cervical dystonia","volume":"15","author":"Sethi","year":"2012","journal-title":"J. Med. Econ."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3111\/13696998.2014.925462","article-title":"Satisfaction with botulinum toxin treatment in post-stroke spasticity: Results from two cross-sectional surveys (patients and physicians)","volume":"17","author":"Bensmail","year":"2014","journal-title":"J. Med. Econ."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.2147\/PPA.S106560","article-title":"Striving for more good days: Patient perspectives on botulinum toxin for the treatment of cervical dystonia","volume":"10","author":"Poliziani","year":"2016","journal-title":"Patient Prefer. Adherence"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/4\/280\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:14:35Z","timestamp":1760123675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/4\/280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["toxins15040280"],"URL":"https:\/\/doi.org\/10.3390\/toxins15040280","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]}}}